GLP-1 medications have become increasingly popular for managing type 2 diabetes and supporting weight management. While these treatments offer significant health benefits, their growing use has prompted questions about their potential effects on eye health.
For patients taking these medications, an eye health assessment can help evaluate the condition of the retina, address individual concerns and determine whether further monitoring may be appropriate. Moorfields Private has introduced a specialist eye health assessment service for GLP-1 users, offering access to consultant-led ophthalmic evaluation and advanced retinal imaging.
Why Might GLP-1 Users Consider an Eye Health Assessment?
GLP-1 receptor agonists, including semaglutide and tirzepatide, are used for conditions such as type 2 diabetes and weight management, depending on the specific medication and its approved indications.
Although current evidence does not suggest that every patient taking a GLP-1 medication requires additional eye monitoring solely because of its use, patients with existing eye conditions, changes in their vision or concerns about their ocular health may benefit from discussing a specialist assessment with their healthcare provider.
This may be particularly relevant to people using these medications for weight management who are not covered by routine diabetic eye screening programmes.
Moorfields Private’s Specialist Eye Health Assessment Service
Moorfields Private has launched a dedicated eye health assessment service for patients taking GLP-1 medications. The service provides a comprehensive evaluation of eye health, including specialist assessment, retinal imaging and personalised advice on whether additional monitoring or further investigation is needed.
Ms沙龙恒, consultant ophthalmic surgeon at Moorfields Private and Moorfields Eye Hospital NHS Foundation Trust, highlighted the importance of addressing patients’ concerns as the use of these medications expands.
“GLP-1 medications have delivered significant health benefits for many patients, particularly those living with obesity and type 2 diabetes. However, as their use becomes more widespread, patients are understandably asking questions about potential effects on eye health.”
– Ms Sharon Heng
Consultant Ophthalmic Surgeon, Moorfields Private and Moorfields Eye Hospital NHS Foundation Trust
Ms Heng noted that evidence surrounding the ocular effects of these medications continues to evolve. While most patients do not need to be concerned, those with existing eye conditions or changes in their vision may value the reassurance of a specialist assessment.
With consultant ophthalmologists and diagnostic technologies available, Moorfields Private offers a specialist setting for patients seeking a more detailed assessment of their eye health while taking GLP-1 medications.
The service includes access to advanced retinal imaging technologies, such as optical coherence tomography (OCT) and ultrawide-field retinal imaging. These investigations can help ophthalmologists examine the retina in greater detail and determine whether further tests, treatment or ongoing monitoring may be appropriate.
The service launch was also reported by Eyewire News, highlighting the growing attention to eye health among people using GLP-1 medications.
What Should Patients Know About Semaglutide and Vision?
In February 2026, the UK Medicines and Healthcare products Regulatory Agency (MHRA) updated its guidance on semaglutide-containing medicines to include a warning about non-arteritic anterior ischemic optic neuropathy (NAION), a very rare adverse effect associated with the medication.
NAION occurs when blood flow to the optic nerve is reduced. It typically causes sudden, painless vision loss in one eye. The MHRA advises patients experiencing sudden vision loss, including partial loss, while taking semaglutide to seek urgent ophthalmic assessment. If NAION is confirmed, the guidance recommends discontinuing semaglutide.
Research into possible associations between GLP-1 medications and other eye conditions, including diabetic retinopathy and age-related macular degeneration, is also ongoing.
These findings do not mean that most patients taking GLP-1 medications will develop eye problems. Patients should discuss individual risks and any concerns about treatment with their prescribing clinician rather than stopping or changing medication independently.
When Should You Seek Urgent Eye Care?
Sudden changes in vision require prompt attention, regardless of whether a person takes GLP-1 medication. Seek urgent medical or ophthalmic assessment if you experience sudden or rapidly worsening vision, a sudden increase in floaters, flashes of light or a dark, curtain-like shadow across your vision. These symptoms can indicate a serious eye condition that requires timely evaluation.
Taking a Proactive Approach to Eye Health
An eye health assessment can help patients understand their individual eye health and whether additional monitoring is appropriate. It is not automatically necessary for everyone taking GLP-1 medication, but it may be worth considering for those with existing eye conditions, new visual symptoms or specific concerns.
For patients seeking specialist evaluation, Moorfields Private’s eye health assessment service offers consultant-led assessment, advanced retinal imaging and personalised guidance. Discussing your circumstances with an ophthalmologist can help you make informed decisions about monitoring your eye health while continuing treatment under the guidance of your prescribing clinician.
